Testosterone Solution Found Safe, Effective for Hypogonadal Men

Share this content:
A testosterone solution was safe and appeared to improve sex drive and energy in hypogonadal men.
A testosterone solution was safe and appeared to improve sex drive and energy in hypogonadal men.

(HealthDay News) — Once-daily 2% testosterone solution (T-sol) is safe and effective for sex drive and energy in hypogonadal men, according to a study published in The Journal of Urology.

Gerald Brock, MD, from the University of Western Ontario in London, Canada, and colleagues examined the continued safety and efficacy of T-sol in a 6-month open-label extension study following a 3-month placebo controlled study. Five hundred fifty-eight participants with hypogonadism (mean age, 55 years) were enrolled in the open-label study. Of these, 275 and 283 had previously received placebo and T-sol, respectively, in the double-blind phase.

The researchers found that 60% and 66% of the participants in the formerly placebo and continuing active treatment groups, respectively, had total testosterone levels within the normal range at the completion of the open-label phase. During the open-label phase, there were baseline to end point improvements for both groups in the Sexual Arousal, Interest, and Drive score (both P<.001) and Hypogonadism Energy Diary score (both P<.001). There were no reports of new safety concerns.

"Once-daily T-sol administered for 6 months in an open-label study did not indicate new safety concerns, and the outcomes of low sex drive and low energy showed further improvement after the double-blind phase," the researchers wrote.

Disclosures: Several authors disclosed financial ties to pharmaceutical companies, including Eli Lilly, which assisted with trial administration.

Reference

  1. Brock G, Heiselman D, Knorr J, Ni X, Kinchen K. 9-Month Efficacy and Safety Study of Testosterone Solution 2% for Sex Drive and Energy in Hypogonadal Men: Results of a 6-Month Open Label Extension of a 3-Month Double-Blind Study. J Urol. 2016. doi:10.1016/j.juro.2016.04.065.
You must be a registered member of Endocrinology Advisor to post a comment.

Sign Up for Free e-Newsletters

CME Focus